Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 19;5:479. doi: 10.1038/s42003-022-03432-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a HRMVECs were treated with IL-33 (20 ng/mL) for various time periods, cell extracts prepared and analyzed by Western blotting for Jagged1, Jagged2, DLL1, DLL3, DLL4 levels and normalized to β-tubulin. b Retinal tissue extracts from C57BL/6 normoxia and various time periods of hypoxia were analyzed for the indicated proteins by Western blotting and normalized to β-tubulin. c At P15, retina tissue extracts from IL-33^+/+ and IL-33^−/− mice pups were analyzed by Western blotting for indicated proteins and normalized to β-tubulin. n = 6 animals per group. d Upper panel, HRMVECs were transfected with control siRNA (siControl) or Jagged1 siRNA (siJagged1), after 48 h cell extracts were analyzed for Jagged1 levels by Western blotting and normalized to β-tubulin. Lower panel, all the condition are same as in upper panel, except that the cells were analyzed for IL-33 (20 ng/mL)-induced sprouting. e–g All the condition are same as in upper panel d except HRMVECs were treated with and without IL-33 (20 ng/mL) and subjected to migration (e, f), and tube formation assay (g). h Cell extracts treated with various time periods of IL-33 (20 ng/mL) were analyzed by Western blotting for the indicated proteins. i Quiescent HRMVECs were first treated with QNZ (10 μM, NFkappaB inhibitor) for 30 min, followed by with or without IL-33 (20 ng/mL) treatment for 2 h. The cell lysates were prepared and analyzed for Jagged1 levels by Western blotting and normalized to β-tubulin. j Everything was same as in b, except that retinal extracts were analyzed for the indicated proteins by Western blotting. k At P15, the retinal tissue extracts from IL-33^+/+ and IL-33^−/− mice pups subjected to normoxia and hypoxia analyzed for indicated proteins by Western blotting. n = 6 animals per group. The bar graphs show quantitative analysis of three independent experiments, expressed as Mean ± SD. *P < 0.05 vs control siRNA or normoxia, **p < 0.05 vs control siRNA + IL-33. Scale bar represents 50 μm in d.